X0306 4 2017-04-24 0 0001510580 Kite Pharma, Inc. KITE 0001198321 CHAMPSI FARAH C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 1 0 0 0 Common Stock 2017-04-24 4 S 0 25818 82.34 D 122225 I See Footnote Common Stock 2017-04-25 4 S 0 31467 82.56 D 90758 I See Footnote Common Stock 2017-04-25 4 S 0 15316 83.29 D 75442 I See Footnote Common Stock 2017-04-26 4 S 0 51112 82.72 D 24330 I See Footnote Common Stock 2017-04-26 4 S 0 200 83.06 D 24130 I See Footnote Common Stock 79152 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.07 to $82.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.05 to $83.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ David M. Tanen, Attorney-in-Fact 2017-04-26